Zevalin works as initial therapy for follicular non-Hodgkin lymphoma

01/24/2013 | Medscape (free registration)

Initial treatment with the radioimmunotherapy Zevalin, also called 90-yttrium ibritumomab tiuxetan, allowed 35% of 59 patients with follicular non-Hodgkin lymphoma to have long-lasting responses, according to a study published in the Journal of Clinical Oncology. Patients' overall response rate at six months was 86%, and 41% of patients showed complete response. "In our opinion, radioimmunotherapy is a particularly attractive therapy for older patients, patients with significant comorbidity, or patients who refuse chemotherapy," researchers said.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX